Biotech · Public company · La Jolla, CA, US
Ensysce Biosciences, Inc.
Ticker ENSC · SEC CIK 0001716947
Track this companyFree. Adds Ensysce Biosciences, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials92 recruiting or active
Pipeline programs16From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline16
- PF614 capsulePhase 3 · Postoperative Pain, AcuteClinicalTrials.gov · fetched Nov 12, 2026
- PF614Phase 2 · Acute PainClinicalTrials.gov · fetched Nov 12, 2026
- Nafamostat MesilatePhase 1 · PharmacokineticsClinicalTrials.gov · fetched Nov 12, 2026
- Nafamostat MesylatePhase 1 · PharmacokineticsClinicalTrials.gov · fetched Nov 12, 2026
- Naltrexone HydrochloridePhase 1 · PharmacokineticsClinicalTrials.gov · fetched Nov 12, 2026
- Naltrexone HydrochloridePhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- Naltrexone HydrochloridePhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- OxycodonePhase 1 · Recreational Drug UseClinicalTrials.gov · fetched Nov 12, 2026
- Oxycodone extended-releasePhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- Oxycodone Hydrochloride 40 mgPhase 1 · Recreational Drug UseClinicalTrials.gov · fetched Nov 12, 2026
- OxyContinPhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- PF614Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- PF614Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- PF614Phase 1 · Recreational Drug UseClinicalTrials.gov · fetched Nov 12, 2026
- PF614 capsulePhase 1 · PharmacokineticsClinicalTrials.gov · fetched Nov 12, 2026
- PF614 solutionPhase 1 · PharmacokineticsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301)PHASE3 · RECRUITING · started Dec 9, 2025ClinicalTrials.gov NCT06602271 · fetched Nov 12, 2026
- Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)PHASE1 · RECRUITING · started Nov 24, 2024ClinicalTrials.gov NCT06500793 · fetched Nov 12, 2026
- Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201)PHASE2 · COMPLETED · started Oct 5, 2023ClinicalTrials.gov NCT06629402 · fetched Nov 12, 2026
- A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)PHASE1 · COMPLETED · started Oct 5, 2022ClinicalTrials.gov NCT05571345 · fetched Nov 12, 2026
- A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)PHASE1 · COMPLETED · started Jun 10, 2022ClinicalTrials.gov NCT05567354 · fetched Nov 12, 2026
- Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)PHASE1 · COMPLETED · started Dec 1, 2021ClinicalTrials.gov NCT05090280 · fetched Nov 12, 2026
- Evaluation of Oral PF614 Relative to OxyContin (PF614-102)PHASE1 · COMPLETED · started Sep 8, 2021ClinicalTrials.gov NCT05043766 · fetched Nov 12, 2026
- Oral Nafamostat in Healthy Volunteers (NAF-101)PHASE1 · COMPLETED · started Sep 21, 2020ClinicalTrials.gov NCT04406415 · fetched Nov 12, 2026
- Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)PHASE1 · COMPLETED · started Nov 16, 2016ClinicalTrials.gov NCT02454712 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K/A · 8-K/ASEC EDGAR · filed Oct 16, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 29, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 25, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 24, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K/A · 8-K/ASEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 15, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 22, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 15, 2026 · fetched Nov 12, 2026
NIH awards3
- PF614-MPAR: clinical development of opioid with oral overdose protectionFiscal year 2026 · $5.3MNIH RePORTER 5U01DA059791-03 · fetched Nov 12, 2026
- PF614-MPAR: clinical development of opioid with oral overdose protectionFiscal year 2025 · $5.3MNIH RePORTER 5U01DA059791-02 · fetched Nov 12, 2026
- PF614-MPAR: clinical development of opioid with oral overdose protectionFiscal year 2024 · $4.6MNIH RePORTER 1U01DA059791-01A1 · fetched Nov 12, 2026